New NYSE Alert [Inside]

AwesomeStocks Don’t want emails from us anymore? Click [here]( to unsubscribe. Hello! New Alert: NanoViricides, Inc. (NYSE American: NNVC) NNVC is our new NYSE high volatility alert and a previous big winner on multiple occasions. We first alerted NNVC earlier this year in May when NNVC was trading under 2.12, it consistently rallied afterwards, reaching a high of 3.59, gains of +69% in a month! We alerted it again in June when it was around 1.88, after which over the past month plus it rallied today to a high of 2.55, experiencing gains of +35%! NNVC could present a continued breakout opportunity. Since our last update, over the past month, NNVC announced multiple developments. NNVC is a NYSE listed “development stage company that is creating special purpose nanomaterials for antiviral therapy”. The Company's “novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them”. NNVC’s “lead drug candidate is NV-387 for the treatment of RSV, COVID-19, Long COVID, Influenza, and other respiratory viral infections”. In addition, the company’s “other advanced candidate is NV-HHV-1 for the treatment of Shingles (previously referred to as NV-HHV-101)”. As the company further explains: - “NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles.” Importantly: - “The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.” NNVC is also “developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others”. Importantly: “NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel.” “NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses.” Since our last update, in June, the company announced: “Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect” As the company further explained: “This unusual but highly desirable, extended flat time profile of blood concentration of orally given NV-387 enables sustained antiviral effect over a long period of time, allowing infrequent dosing regimens.” Furthermore: “The flat time profile of NV-387 indicates that even at very high dosings, its blood concentration is unlikely to result in unwanted side effects. Typical drugs result in a rapid rise in blood concentration of the drug in generally the first hour to a peak, thereafter rapidly exponentially decreasing to baseline in 3-6 hours. In order to ensure that the concentration of the drug is sufficiently high to provide antiviral effect at say 2-4 hours from dosing, the drug dose chosen would be relatively high, and can therefore result in a substantially greater drug concentration in the beginning, which can result in unwanted side effects. Therefore, a sustained, nearly flat drug concentration profile is highly sought-after.” On June 20th, the company announced: “A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model” Here are some of the company’s comments from this press release: "We believe that the lung protection afforded by NV-387 is a very important result. The most severe cases that lead to hospitalization and fatalities in respiratory viral infections involve lung damage as an important factor," said Anil R. Diwan, PhD, President and Executive Chairman of the Company, adding, "This was starkly evidenced during COVID-19 pandemic wherein the Delta variant that caused severe lung damage also caused the largest number of hospitalizations and fatalities. Influenzas, RSV, COVID can all cause severe lung damage resulting in fatalities." As the company further explained: - “NV-387 Treatment Resulted in Significant Reduction in Lung Infiltration and Lung Cell Death” - “NV-387 Treatment Resulted in Significant Reduction in Mucus Load in the Lungs” - “NV-387 Treatment Resulted in Significantly Greater Survival Improvement Compared to Three Approved Influenza Drugs” - “Viral Resistance to NV-387 is Unlikely as Opposed to Known Evolution of Viral Resistance Against Currently Approved Drugs” - “NV-387 Has Completed Phase I Human Clinical Trial” In addition, the company also announced: “A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides” As the company further explains: “NanoViricides has recently found that its host-mimetic clinical drug candidate NV-387 was substantially superior to the three approved drugs against influenza, namely Oseltamivir (Tamiflu®, Roche), Peramivir (Rapivab®, Biocryst), and Baloxavir (Xofluza®, Shionogi, Roche) in a lethal animal model study of Influenza A/H3N2 virus lung infection.” Most recently, on July 11, the company announced: “A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides” As the company further explains: “NV-387 has completed Phase I clinical trials with no reported adverse events, indicating excellent safety. Closing of the clinical trial site - hospital site itself - is in progress, with different audits taking place to ensure regulatory compliance. Statistical data analysis is expected to begin thereafter. We are eagerly awaiting further information and will provide updates as it becomes available.” “We have started planning Phase II clinical studies of NV-387 as a treatment for RSV and other indications including Influenza and COVID, as the Phase I clinical trial comes to a close. We plan on taking the drug NV-387 forward on the fastest regulatory path feasible towards regulatory approvals in different countries and jurisdictions including the USA.” In addition, on Wednesday, the company announced: - “COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides” Make sure to do your own due diligence. Sources: [PR1]( [PR2]( [PR3]( [PR4]( [PR5]( [Website]( [Chart]( Happy Trading! AwesomeStocks Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose. DISCLAIMER You should read and understand this disclaimer in its entirety before joining the website or email/blog list of AwesomeStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help. The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete. The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete. Owners and operators of the Publisher have been compensated ten thousand dollars by bank wire transfer on 7/23/24 for the distribution of this advertisement about NNVC dated 7/24/24. Previously, owners and operators of the Publisher have been compensated ten thousand dollars by bank wire transfer on 6/14/24 for the distribution of a prior advertisement about NNVC. Previously, owners and operators of the Publisher have been compensated ten thousand dollars by bank wire transfer on 5/15/24 for the distribution of a prior advertisement about NNVC. Previously, owners and operators of the Publisher have been compensated ten thousand dollars by bank wire transfer on 5/8/24 for the distribution of a prior advertisement about NNVC. Prior to the past year, at the time of publication, we disclosed our compensation for the distribution of advertisements about NNVC. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time. You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at info@AwesomeStocks.com to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: www.AwesomeStocks.com/Disclaimer and www.AwesomeStocks.com/Privacy-Policy By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. Our records indicate that {EMAIL} requested and confirmed to be added to AwesomeStocks.com on March 5, 2023. [Click Here To Unsubscribe]( 6020 Bent Pine Dr Orlando Florida 32822 USA [Unsubscribe]( | [Change Subscriber Options](